Damià Tormo

Damià has been widely recognized for his capacity to combine a brilliant scientific career with that of an entrepreneur and investor. He received his PhD in immunology and molecular genetics from the Rheinische Friedrich-Wilhelms-Universität Bonn (Germany) and holds a Masters in international management of biotechnology from the IE Business School. During his scientific tenure he was actively engaged in R&D in and for institutions including University of Cambridge (UK), Michigan University (USA) and Centro Nacional de Investigaciones Oncológicas (CNIO) and authored publications in peer reviewed journals including Nature and Cancer Cell. As a founder and managing partner of Columbus Venture Partners, he has helped developed numerous biotechnology companies in Europe and the US, serving on the Board of Artax Biopharma, Viralgen Vector Core, Polypeptide Therapeutic Solutions, Bioncotech Therapeutics and Sanifit.